(NYSE: ABBV) Abbvie's forecast annual revenue growth rate of 6.69% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 7.23%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.57%.
Abbvie's revenue in 2025 is $57,367,000,000.On average, 7 Wall Street analysts forecast ABBV's revenue for 2025 to be $105,845,451,859,065, with the lowest ABBV revenue forecast at $104,333,389,671,117, and the highest ABBV revenue forecast at $107,487,517,776,995. On average, 7 Wall Street analysts forecast ABBV's revenue for 2026 to be $114,664,450,370,160, with the lowest ABBV revenue forecast at $111,913,272,356,398, and the highest ABBV revenue forecast at $118,673,701,247,020.
In 2027, ABBV is forecast to generate $122,993,473,411,206 in revenue, with the lowest revenue forecast at $119,846,912,575,896 and the highest revenue forecast at $127,291,831,471,496.